Casper Breum was previously CEO of ilochip A/S, a venture-backed company focused on development of diagnostic biochips. Before that, he held different positions at H. Lundbeck A/S most recently in corporate business development and strategy, where he gained broad international experience. Prior to his work at H. Lundbeck, Casper worked for Novo Nordisk A/S and Niels Clauson-Kaas A/S. While working at H. Lundbeck A/S he was a member of the Board of Directors of the Lundbeck Foundation and Lundbeckfond Invest as an employee representative. He is a board member of ATOX Bio, Aura Biosciences, DySIS Medical, Sanifit and Spero Therapeutics (NASDAQ: SPRO). Casper has an M.S. in Organic Chemistry and an MBA.